We exist to make childbirth safe for mothers and babies

We are proud to share that VitalTrace has been awarded $500,000 as part of the Government of Western Australia’s Future Health Research and Innovation (FHRI) Fund’s Innovative Solutions – Precision Health program.

VitalTrace is poised to revolutionise childbirth with DelivAssure, following our world-first clinical trial (read about it here.

This recent grant win allows us to extend our impact beyond childbirth and into a baby’s first days of life. Our continuous lactate monitoring (CLM) technology will be adapted to detect elevated lactate in neonates, an early indicator of neonatal sepsis, which has a mortality rate of 17-25%.

Lactate is a vital biomarker of metabolic stress, rising in not only sepsis, but other serious complications such as congenital heart disease and necrotising enterocolitis.

With our CLM technology, clinicians could gain real-time and accurate insights into neonatal wellbeing without repeated heel pricks or blood draws, facilitating early diagnosis, better management and reducing pain, trauma and blood loss in critically ill newborns.

Thank you to the FHRI for supporting our mission to significantly improve newborn outcomes and drive precision health innovation in Western Australia.

See the announcement here.

A breakthrough in childbirth care and a proud moment for the VitalTrace team. Our continuous lactate monitor for childbirth, DelivAssure, has been featured on a number of media platforms, including the ABC, as a potential breakthrough.

‍Full ABC News feature here
‍

A moment of thanks on the achievement of the recent clinical trials:

We want to especially thank our Chief Medical Officer Jonathan Morris, the tireless Sharon McCracken, and our long-time collaborator Jane Pillow, who have been integral to our progress.

Thank you to our Principal Investigators across our clinical trials: A/Professor Sean Seeho, Penny Sheehan, Daniel Rolnik and Scott White. We’re incredibly grateful to the clinical teams and hospitals who made these trials possible across Royal North Shore Hospital, Monash Health, King Edward Memorial Hospital and Box Hill Hospital - Eastern Health.

The mothers and babies who took part in our trials are also at the heart of our work. We are endlessly appreciative for their participation.

Also with thanks to our partners and supporters: The University of Western Australia, University of Sydney, University of Technology Sydney, Australian Government and Government of Western Australia's Future Health Research and Innovation (FHRI) and Department of Jobs, Tourism, Science and Innovation (JTSI), Fund WA and Artesian (Alternative Investments).

Most of all, a huge thank you to our entire VitalTrace team whose hard work and dedication everyday have lead to this outcome.

Our first peer-reviewed journal article has been published in The SMFM Pregnancy Journal — the official open-access journal of the Society for Maternal-Fetal Medicine (SMFM) based in Washington, DC.

In collaboration with The University of Western Australia, our study demonstrates the capability of our technology, DelivAssure, in detecting early signs of fetal lactic acidosis, highlighted by the strong correlation between sensor current and venous blood lactate levels.  

We're proud to contribute to the growing body of evidence aimed at improving outcomes for mothers and babies — DelivAssure has the potential to revolutionise intrapartum care by enabling crucial early detection and management of fetal asphyxia during labor and delivery.

📰 Read the full article here: https://onlinelibrary.wiley.com/doi/10.1002/pmf2.70017

We're incredibly grateful to our collaborators, clinical partners, and the SMFM editorial team for supporting this work.